In silico analysis of antihypertensive and hepatotoxicity potential of the n-butanol fraction of the methanol extract of cantaloupe (Cucumis melo var. cantalupensis)

DOI: https://doi.org/10.22435/hsji.v11i2.3629

Dian Laila Purwaningroom¹, Dianita Rifqia Putri¹, Galuh Wening Permatasari²

¹Faculty of Health Sciences, Universitas Muhammadiyah Ponorogo, Jawa Timur, Indonesia
²Indonesian Research Institute for Biotechnology and Bioindustry (IRIBB), Bogor, Indonesia

Corresponding author: Dian Laila Purwaningroom
Email: dianlaila@umpo.ac.id

Received: June 4, 2020; Revised: November 10, 2020; Accepted: December 7, 2020

Abstract

Background: Hypertension is a major cardiovascular disease risk factor. Indonesian people tend to consume herbal medicine to maintain hypertension therapy, i.e. cantaloupe (Cucumis melo var. cantalupensis). However, the mechanism of action of cantaloupe in lowering blood pressure and toxicity potential for long term consumption is unclear. The study aimed to analyze the antihypertensive mechanism of cantaloupe and its toxic potential through the in silico approach.

Methods: The dried cantaloupe powder was macerated using absolute methanol, then fractionated using n-butanol. The phytochemical test was done by LC-MS method, then the bioactive compounds were traced to their SMILES in the PubChem. The QSAR analysis of the antihypertensive potential was done using the PASS server. The toxicity class and hepatotoxicity potential were analyzed using ProTox-II, followed by networking analysis using STITCH and STRINGdb.

Results: At least 434 types of compounds were shown in the n-butanol fraction of the methanol extract of cantaloupe (BFMEC). Based on the networking analysis, BFMEC may work in lowering blood pressure through the action mechanism of the amlodipine compound-like, which stabilizes voltage-gated L-type calcium channels in an inactive conformation, thus, prevents calcium-dependent myocyte contraction and vasoconstriction. BFMEC presumably has hepatotoxic through the action mechanism of itraconazole compound-like inhibited cytochrome P450-dependent enzymes, affecting the impairment of ergosterol synthesis, and efavirenz which has neurotoxic effects. The inhibition of cytochrome P450 may cause drug toxicity and liver damage.

Conclusion: BFMEC may work in lowering blood pressure through the action mechanism which stabilizes voltage-gated L-type calcium channels in an inactive conformation. (Health Science Journal of Indonesia 2020;11(2):106-14)

Keywords: in silico, antihypertensive, hepatotoxicity, cantaloupe
Hypertension is a major risk factor in cardiovascular disease. Globally, there are about one third of people with hypertension who are undiagnosed, and half of those diagnosed do not take antihypertensive drugs. The drug can be considered as a xenobiotic group, which are compounds originating from outside the body that enters the body. The liver plays an important role in the metabolism of xenobiotics, making this organ vulnerable to chemicals that are exposing ubiquitously. Most of the liver damage caused by chemicals begins with the metabolism of chemicals, such as reactive intermediates such as electrical compounds or free radicals, which can alter the structure and function of cellular cell molecules.

Indonesian people tend to consume herbal medicine to maintain good health. Jamu is still very popular in rural as well as in urban areas. Based on its traditional use jamu is being developed into a rational form of therapy, by herbal practitioners and in the form of phytopharmaceuticals. Jamu has acquired a potential benefit, both economically and clinically. We surveyed the most frequently used plants in jamu that have also been investigated regarding their constituents and pharmacological effects. The Indonesian government has divided the preparation of medicinal plants into three categories, i.e. jamu, standardized herbal medicines and fitofarmaka (phytomedicines, including hypertension therapy). Cantaloupe (Cucumis melo L) is often used in hypertension therapy in Indonesia, especially among Javanese people. Some studies showed that Cucumis melo L inhibits phenylephrine-mediated vasoconstriction in mice. But it is not yet known the mechanism of action of cantaloupe in lowering blood pressure. It also not known the potential of toxicity if consumed in the long term.

Nowadays, the process of drug discovery which begins with the bioinformatics method is very popular. This is because the method efficiently reduce the occurrence of trials and errors during in vitro and in vivo studies. Therefore, this study aimed to analyze the antihypertensive and hepatotoxicity potential of the n-butanol fraction of the methanol extract of cantaloupe (Cucumis melo var. cantalupensis) (BFMEC) through the bioinformatics approach.

**METHODS**

**Tools and materials**

The materials used in extraction are cantaloupe fruits, methanol absolut as maceration solvent, and n-Butanol as fractionation solvent. Material used in Phytochemical tests were 0.1% Formic acid in Water, 0.1% Formic acid in Acetonitrile as LC-MS Solvent and Hypersil GOLD aQ 50 x 1 mm x 1.9 u. Tools used in maceration were analytical balance, beaker glass, wood stirrer, cloth, funnel, rotary evaporator, and extract bottle. Tools used in phytochemical test were Thermo Scientific Dionex Ultimate 3000 RSLCnano with microflow meter. The tool used for tracing the canonical SMILES was PubChem (https://pubchem.ncbi.nlm.nih.gov). Bioinformatic tools used in this study were Way2Drug (http://www.pharmaexpert.ru/passonline/) to analyze antihypertensive potential; STITCH (http://stitch.embl.de/) to analyze ligand-protein interactions, STRINGdb (https://string-db.org) to analyze target proteins interactions.

**Cantaloupe extraction and phytochemical testing**

Cantaloupe fruits we obtained in April 2018 from Materia Medica Batu, were cut and air dried for 7 days. The dried cantaloupe was crushed into powder for subsequent maceration. Extraction was carried out by maceration method. Two hundred grams of cantaloupe powder were macerated in 3 liters of absolute methanol in beaker glass for 3 days. The extract is then filtered and dried using a rotary evaporator. Fractionation is done using n-Butanol. The BFMEC stored at 4°C until used. Phytochemical tests were carried out by the method Liquid Chromatography-Mass Spectrometry using Thermo Scientific Dionex Ultimate 3000 RSLCnano with microflow meter. Solvents: A= 0.1% Formic acid in Water; B= 0.1% Formic acid in Acetonitrile. Analytical column: Hypersil GOLD aQ 50 x 1 mm x 1.9 u particle size. Analytical flow rate: 40 uL/min. Flow gradient: Run time 30 minutes; Column oven 30°C.

**Analysis of antihypertensive potential**

The names of the compounds contained in BFMEC from LC-MS test result are traced to the canonical SMILES via PubChem (https://pubchem.ncbi.nlm.nih.gov). BFMEC antihypertensive potential was analyzed by inputting SMILES in Way2Drug (http://www.pharmaexpert.ru/passonline/), potentially antihypertensive compounds with PDB> 0.3 were selected. The interaction of antihypertensive compounds with their predicted functional partners was analyzed using STITCH (http://stitch.embl.de/). Interactions between target proteins were analyzed using STRINGdb (https://string-db.org).
**Analysis of hepatotoxicity potential**

The potential of BFMEC hepatotoxicity was analyzed by inputting SMILES on ProTox-II (http://tox.charite.de/protox_II/). In ProTox-II, the hepatotoxicity potential of each compound was indicated by “active” or “inactive” information along with the probability of hepatotoxicity score. We chose compounds that fell into the “active” category. Interactions of antihypertensive compounds with predicted functional partners were analyzed using STITCH. Interactions between target proteins were analyzed using STRINGdb.

**Ethical clearance**

This research doesn’t require ethical clearance due to the absence of human involvement as research subjects.

**RESULTS**

**Cantaloupe extraction and phytochemical testing**

Extraction carried out by maceration with methanol solvent on 200 grams of cantaloupe powder simplicia produced 16.03 grams of crude extract and 2.214 grams of n-butanol fraction. Phytochemical tests were carried out using the LC-MS method, showed that there were 434 types of bioactive compounds (Figure 1).

We traced to the canonical SMILES via of the 434 bioactive compounds via PubChem (https://pubchem.ncbi.nlm.nih.gov). With these canonical SMILES we traced their antihypertensive potential. BFMEC antihypertensive potential was analyzed by inputting the canonical SMILES of 434 bioactive compounds in Way2Drug (http://www.pharmaexpert.ru/passonline/), potentially antihypertensive compounds with Pa > 0.3 were selected.

**Analysis of antihypertensive potential**

Based on the results of the analysis of antihypertensive potential on Way2Drug, there were 24 compounds that had the potential as antihypertensive drugs in BFMEC marked with a value of Pa > 0.3 (data not shown). However, only 3 compounds (Table 1) that displayed direct interaction with the target proteins (Table 2); amlodipine (2162), okadaic acid (446512), and terfenadine (5405), respectively.

![Figure 1. Chromatogram of the n-butanol fraction of the methanol extract of cantaloupe (Cucumis melo var. cantalupensis) (BFMEC) phytochemical testing using LC-MS method](image)

<table>
<thead>
<tr>
<th>No</th>
<th>Name</th>
<th>Compound ID</th>
<th>Pa score of antihypertensive</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>[Similar to: Amlodipine; ΔMass: 92.0960 Da]</td>
<td>2162</td>
<td>0.917</td>
</tr>
<tr>
<td>2</td>
<td>[Similar to: Okadaic acid; ΔMass: 540.3353 Da]</td>
<td>446512</td>
<td>0.459</td>
</tr>
<tr>
<td>3</td>
<td>[Similar to: Terfenadine; ΔMass: -18.0060 Da]</td>
<td>5405</td>
<td>0.329</td>
</tr>
</tbody>
</table>
Table 2 showed predicted functional partners of the active compound in the BFMEC with the potential of antihypertensive. Figure 2b showed the interaction between proteins that were targeted by BFMEC compounds. There were interrelated interactions between PPP2R1A, PPP2R4, PPP1CC, and CACNA1C. PPP2R1A, PPP2R4, and PPP1CC are a group of protein phosphatase. IGF1R showed positive interaction with CYP3A4. REN and HRH1 didn’t show any interaction with other target proteins. In this predicted functional partners showed that KCNH2 interacted with CACNA1C, CYP2D6, and CYP3A4.

Table 2. Predicted functional partners of the active compound in the BFMEC with the antihypertensive potential

<table>
<thead>
<tr>
<th>No</th>
<th>Protein Name</th>
<th>Action</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>KCNH2, potassium voltage-gated channel, subfamily H (eag-related), member 2</td>
<td>V V V</td>
<td>0,997</td>
</tr>
<tr>
<td>2</td>
<td>CACNA1C, calcium channel, voltage-dependent, L type, alpha 1C subunit</td>
<td>V V V</td>
<td>0,995</td>
</tr>
<tr>
<td>3</td>
<td>PPP1CC, protein phosphatase 1, catalytic subunit, gamma isozyme</td>
<td>V V</td>
<td>0,993</td>
</tr>
<tr>
<td>4</td>
<td>HRH1, histamine receptor H1</td>
<td>V V V</td>
<td>0,991</td>
</tr>
<tr>
<td>5</td>
<td>REN</td>
<td>V</td>
<td>0,991</td>
</tr>
<tr>
<td>6</td>
<td>CYP2D6, cytochrome P450, family 2, subfamily D, polypeptide 6</td>
<td>V V</td>
<td>0,984</td>
</tr>
<tr>
<td>7</td>
<td>IGF1R, insulin-like growth factor 1 receptor</td>
<td>V</td>
<td>0,975</td>
</tr>
<tr>
<td>8</td>
<td>CYP3A4, cytochrome P450, family 3, subfamily A, polypeptide 4</td>
<td>V V</td>
<td>0,968</td>
</tr>
<tr>
<td>9</td>
<td>PPP2R1A, protein phosphatase 2, regulatory subunit A, alpha</td>
<td>V V</td>
<td>0,963</td>
</tr>
<tr>
<td>10</td>
<td>PPP2R4, protein phosphatase 2A activator, regulatory subunit 4</td>
<td>V</td>
<td>0,959</td>
</tr>
</tbody>
</table>

**Analysis of hepatotoxicity potential**

Based on the results of the analysis of hepatotoxicity potential on ProTox-II, there were 10 compounds in the BFMEC that showed hepatotoxic activity with Pa > 0.3 (data not shown). However, there were only 2 compounds that interacted directly with the target proteins; itraconazole (3793) and efavirenz (64139), mentioned below in the table 3.

Table 3. The active compound in the BFMEC with the hepatotoxicity potential

<table>
<thead>
<tr>
<th>No</th>
<th>Name</th>
<th>Compound ID</th>
<th>Probability of hepatotoxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>[Similar to: Itraconazole; ΔMass: 370.0933 Da]</td>
<td>3793</td>
<td>0.88</td>
</tr>
<tr>
<td>2</td>
<td>[Similar to: Efavirenz; ΔMass: 112.9863 Da]</td>
<td>64139</td>
<td>0.83</td>
</tr>
</tbody>
</table>
Figure 3a. Interactions of the active compound in the BFMEC with the hepatotoxicity potential. 

3b. Interactions between predicted functional partners of the active compound in the BFMEC with the hepatotoxicity potential

Table 4. Predicted functional partners of the active compound in the BFMEC with the hepatotoxicity potential

<table>
<thead>
<tr>
<th>No</th>
<th>Protein Name</th>
<th>Action</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Activation</td>
<td>Inhibition</td>
</tr>
<tr>
<td>1.</td>
<td>CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>2.</td>
<td>CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>3.</td>
<td>ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>4.</td>
<td>CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>5.</td>
<td>CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>6.</td>
<td>CYP3A7 cytochrome P450, family 3, subfamily A, polypeptide 7</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>7.</td>
<td>ALOX5 arachidonate 5-lipoxygenase; cytochrome P450, family 1</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>8.</td>
<td>CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>9.</td>
<td>CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>10.</td>
<td>CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9</td>
<td>V</td>
<td>V</td>
</tr>
</tbody>
</table>

Table 4 showed predicted functional partners of the active compound in the BFMEC with the potential of hepatotoxicity. Figure 3b showed the interaction between proteins that were targeted by BFMEC compounds. There were interrelated interactions between CYP51A1, CYP2C9, CYP3A4, ABCB1, CYP2B6, CYP3A5, and CYP3A7. ALOX5 is interrelated to CYP2B6 and CYP2C9.

DISCUSSION

Hypertension is a major risk factor for cardiovascular disease. It’s about one third of hypertension sufferers are undiagnosed, and of those diagnosed, about half do not use antihypertensive drugs. The World Health Organization (WHO) estimates that high blood pressure directly or indirectly causes the deaths of at least nine million people globally every year. Antihypertensives can be divided into two major groups, the first group are groups that directly or indirectly block the renin-angiotensin system (RAS), for example, ACE inhibitors, angiotensin receptor antagonists (ARA), direct renin inhibitors (DRI), and β-blockers. Although these drugs have several mechanisms of action, their dominant effect is to cause vasodilation. The second group of drugs works by increasing the excretion of water and sodium and reducing intravascular volume. This drug causing vasodilation via non-RAS pathways, for example, diuretics and calcium channel blockers (CCB). This second group action increases RAS activity through negative feedback.

Cantaloupe extraction and phytochemical testing

Maceration with methanol solvent on 200 grams of cantaloupe powder simplicia produced 16.03
grams of crude extract and 2.214 grams of n-butanol fraction. Phytochemical tests were carried out using the LC-MS method showed that there were 434 types of bioactive compounds (Figure 1). Butanol has more than two carbon atoms and has significant solubility in water, shown in Figure 4.

Figure 4. 3D Structure of n-butanol

Butanol is used as a solvent because it can attract semi-polar organic compounds. Semi-polar organic compounds include flavonoids with a slightly lower polarity index below the polarity index of ethyl acetate (polarity index ethyl acetate = 4.3 and n-butanol = 3.9) due to the presence of functional groups attached to it or other compounds that have functional groups are polar.

Anti-hypertensive potential

Based on the results of the analysis of antihypertensive potential on Way2Drug, there were 24 compounds had the potential as antihypertensive drugs in BFMEC marked with a value of Pa> 0.3 (data not shown). However, only 3 compounds (Table 1) displayed direct interaction with the target proteins (Table 2); amlodipine (2162), okadaic acid (446512), and terfenadine (5405), respectively.

Amlodipine has been widely used as a 1,4-dihydropyridine calcium channel blockers (DHP-CCBs) as coadminstrator with statins for hypercholesterolemia and hypertension. To reduce the myopathy risk, the FDA suggests taking amlodipine caused its ability to interact with CYP3A4 as well as CYP3A5. Other studies also mentioned the amlodipine impact among high-risk blood pressure African-American patients with CYP3A4 genotype.

Amlodipine stabilizes voltage-gated L-type calcium channels in an inactive conformation, thus, prevents calcium-dependent myocyte contraction and vasoconstriction. Based on our results, amlodipine interacted directly not only with CYP3A4, but also to REN, and CACNA1C (Figure 2a). Apparently, REN produces angiotensin I from angiotensinogen in plasma. CYP3A4 involve in NADPH-dependent electron transport pathway in the liver microsomes. It has previously been stated that the renin gene is associated with critical hypertension in a number of ethnic groups. A previous study mentioned the effect of amlodipine on REN gene. It was emphasized that blocking of amlodipine calcium channels promotes renin secretion and in vivo expression of the renin gene. These stimulatory effects are almost additive to improvements in renin secretion that arise after renal perfusion pressure decreases unilaterally.

Okadaic acid (OA) is a specific inhibitor of fosfoserin. Okadaic acid interacted with PPP2R4, PPP1CC, and PPP2R1A (Figure 2), all three are phosphatases. Because of this, the function of these phosphatases in cells was observed using this class of molecules. When OA binds to the phosphatase protein(s), various proteins inside the infected cell are hyperphosphorylated, which in turn decreases sodium secretion regulation and solvent cell permeability. High sodium consumption and elevated blood pressure levels are correlated with water accumulation, increased systemic peripheral tolerance, improvements in endothelial function, changes in large elastic artery structure and function, changes in sympathetic response, and autonomic cardiovascular system neural regulation.

Okadaic acid inhibited IGF1R (Figure 2a) which means it might be able to become an anticancer agent.

Terfenadine interacted with KCNH2, CYP3A4, CYP2D6, and HRH1. Terfenadine inhibits KCNH2 (Figure 2a) which functions to mediate the rapid activation component of delayed rectifying potassium current in the heart. Inhibition of this protein will interfere with calcium transportation. Terfenadine also inhibits HRH1, inhibition of this protein can inhibit nerve transmission mediation in the central nervous system.

Table 2 showed predicted functional partners of the active compound in the BFMEC with the potential of anti-hypertensive. Figure 2b showed the interaction between proteins that were targeted by BFMEC compounds. There were interrelated
interactions between PPP2R1A, PPP2R4, PPP1CC, and CACNA1C. PPP2R1A, PPP2R4, and PPP1CC are a group of protein phosphatase. IGF1R showed positive interaction with CYP3A4. REN and HRH1 didn’t show any interaction with other target proteins. In this predicted functional partners showed that KCNH2 interacted with CACNA1C, CYP2D6, and CYP3A4. There was a study found that defects in potassium channel KCNH2 caused numerous congenital and acquired cardiac disease including autosomal-dominant long QT syndrome 2 (LQT2).23

### Hepatotoxicity potential

Based on the results of the analysis of hepatotoxicity potential on ProTox-II, there were 10 compounds in the BFMEC that showed hepatotoxic activity with Pa > 0.3 (data not shown). However, there were only 2 compounds that interacted directly with the target proteins; itraconazole (3793) and efavirenz (64139) (Table 3).

Some of the adverse effect caused by Itraconazole is inducing heart attack24, and other effects such as hypokalemia, aspartate aminotransferase elevation, alanine aminotransferase elevation, gastrointestinal disturbances, diarrhea and a skin rash with a high dose >400 mg/day. Itraconazole’s mechanism of action triggering heart failure is unknown; however, there were no causes that could lead to heart failures such as asthma, cardiomyopathy and other potential factors in the patient.25 Based on the networking analysis, itraconazole acts as an inhibitor for CYP51A1, CYP24A1, CYP1A1, CYP3A4, ABCB1, and ALOX5 (Figure 3a). Itraconazole is one of the triazole antifungal agents which inhibit cytochrome P-450-dependent enzymes that affect the impairment of ergosterol synthesis.26

The CYP group is the Cytochrome P450 family, in liver microsomes, this enzyme is involved in the NADPH-dependent electron transport pathway.27 The inhibition of this enzyme by Itraconazole can cause the disruption of calcium homeostasis in cells. Itraconazole also inhibits the ABCB1 protein, an Energy-dependent efflux pump that is responsible for reducing the accumulation of drugs in multidrug-resistant cells. Thus inhibition of this protein causes an increase in drug accumulation in multidrug-resistant cells.28 Another protein that was inhibited by Itraconazole is ALOX5 (Figure 3). The presence of inhibition in ALOX5 can cause the disruption of the inflammatory process.29 Efavirenz interacted with itraconazole and 6 proteins; CYP3A7, CYP3A4, CYP1A1, CYP2C9, CYP3A5, and CYP2B6, respectively. Itraconazole interacted with efavirenz and 10 proteins; CYP51A1, ABCB1, ALOX5, CYP24A1, CYP3A7, CYP3A4, CYP1A1, CYP2C9, CYP3A5, and CYP2B6, respectively. These proteins are in the cytochrome P450 family, except ABCB1 and ALOX5. Efavirenz showed an interaction with CYP2B6 which was marked by a purple line which showed catalytic action with a score of 0.800. As for the Itraconazole compound and other proteins, there was no significant interaction. It was reported that Efavirenz has neurotoxic effects.30,31

Figure 3b showed the interaction between target proteins in the hepatotoxicity mechanism. Table 4 showed predicted functional partners of the active compound in the BFMEC with the hepatotoxicity potential. This interaction involved cytochrome P450 family. Cytochrome P450 is classified as hemeprotein responsible in the drug metabolism and xenobiotic.32 Drugs with common pathway may involve in the drug-drug interaction33, however not all drugs have Cytochrome P450 activity. Drugs with Cytochrome P450 activity may be inhibitors, inducers, or substrates for a specific Cytochrome P450 enzymatic pathway, which may alter the metabolism of agents simultaneously administrated. Drugs that inhibit enzymatic pathway of Cytochrome P450 may cause increased concentration of other drugs metabolized by the same pathway and resulting in drug toxicity.32 In conclusion, the BFMEC may work in lowering blood pressure through the action mechanism of the amlodipine compound-like, which stabilizes voltage-gated L-type calcium channels in an inactive conformation, thus, prevents calcium-dependent myocyte contraction and vasoconstriction. The BFMEC may potentially hepatotoxic through the action mechanism of itraconazole which inhibits cytochrome P-450-dependent enzymes that affect the impairment of ergosterol synthesis and efavirenz which has neurotoxic effects.

**Acknowledgments**

This researcher would like to thank the Directorate General of Research and Development Strengthening (DGRDS) of the Ministry of Research, Technology, and the Higher Education of the Republic of Indonesia for funding this research (037/SP2H/LT/K7/KM/2018).
REFERENCES


